瑞格列奈与格列齐特治疗老年2型糖尿病的疗效与安全性

Therapeutic Effect and Safety of Repaglinide and Gliclazide in the Treatment of Elderly Type 2 Diabetes Mellitus

观察瑞格列奈与格列齐特治疗老年2型糖尿病（T2DM）的疗效与安全性。方法：225例年龄〉60岁的T2DM患者，随机分为瑞格列奈组（n=112）与格列齐特组（n=113），瑞格列奈组给予瑞格列奈O．5—2mg，po，tid，格列齐特组给予格列齐特缓释片30—120mg，p0，qd，疗程12周。观察两组患者治疗前后的空腹血糖（FPG）、餐后2h血糖（2hPG）、糖化血红蛋白（HbAlc）、总胆固醇（Tc）、三酰甘油（TG）变化情况及不良反应发生情况，比较两组疗效。结果：治疗后，两组患者的FPG、2h PG、HbAlc、TC均较治疗前显著降低（P〈0．05或0．01），且瑞格列奈组患者2h．PG下降更显著（P〈0．05），瑞格列奈组与格列齐特组总有效率（91．8％摊86．2％）、低血糖发生率（4．5％vs8．2％）及不良反应发生率（6．4％vs10．1％）差异均无统计学意义（P〉0．05）。结论：格列齐特缓释片与瑞格列奈治疗老年T2DM疗效显著，安全性较好。

To evaluate the clinical efficacy and safety of repaglinide and gliclazide in the treatment of elderly type 2 di- abetes mellitus （T2DM）. Methods： A total of 225 T2DM patients with the age over 60 were enrolled and randomly divided into repa- glinide group （ n = 112） and glielazide group （ n = 113 ）. The repaglinide group was given repaglinide 0.5～2 rag, po, tid, while the gliclazide group was given gliclazide modified release tablets 30 ~ 120 mg, po, qd, both with the treatment course of 12 weeks. The level of FPG, 2h PG, HbA1C, TC and TG and the side effects were observed and the clinical efficacy was compared between the two groups. Results： The level of FPG, 2h PG, HbAlc and TC in the two groups showed significant decrease after the treatment （P 〈 0.01 or P 〈 0.05 ）, and the level of 2h PG was decreased more significantly in the repaglinide group （P 〈 0.05 ）. There were no significant differ- ences in the total effective rate （91.8% vs 86.2% ）, hypoglycemia incidence （4.5% vs 8.2% ） and ADR incidence （6.4% vs 10.1% ） in the two groups （P 〉0.05）. Conclusion： Both repaglinide and gliclazide show safe and reliable efficacy in the treatment of elderly T2DM.